Achillion Pharmaceuticals, Inc. Receives Notice From NASDAQ
11/18/2009 8:32:12 AM
More...
|
Achillion Pharmaceuticals, Inc. Reports Third Quarter Results
11/6/2009 8:45:28 AM
More...
|
Achillion Pharmaceuticals, Inc. Completes Phase 1a Trial of ACH-1625; Begins Dosing in Phase 1b Segment With HCV-Infected Patients
9/28/2009 8:37:06 AM
More...
|
Achillion Pharmaceuticals, Inc. to Present At the Thomas Weisel Partners Annual Healthcare Conference
9/4/2009 8:56:32 AM
More...
|
Achillion Pharmaceuticals, Inc. to Present At the Canaccord Adams 29th Annual Global Growth Conference
8/3/2009 10:44:47 AM
More...
|
Achillion Pharmaceuticals, Inc. Enters $15 Million Standby Equity Distribution Agreement
7/6/2009 11:19:15 AM
More...
|
Achillion Pharmaceuticals, Inc. Announces First-in-Human Dosing of ACH-1625 for Treatment of Hepatitis C
6/29/2009 9:54:22 AM
More...
|
Achillion Pharmaceuticals, Inc. to Present At the Canaccord Adams Hepatitis C Conference
6/9/2009 4:27:49 PM
More...
|
Achillion Pharmaceuticals, Inc. to Present At Upcoming Conferences
6/2/2009 10:00:59 AM
More...
|
Achillion Pharmaceuticals, Inc. Reports First Quarter Financial Results and Provides Pipeline Update
5/15/2009 9:40:39 AM
More...
|
|